Nasus Pharma Ltd. (NSRX)
Nasus Pharma will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$8.00 - $10.00
Shares Offered
1,250,000
Deal Size
$11.25M

Company Description

Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions.

Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active powder-based intranasal technology, or PBI, specialized products.

To help achieve this we are focused on developing NS002, an intranasal powder Epinephrine nasal spray for the treatment of type 1 severe allergies and anaphylaxis, or Intranasal Epinephrine, and we also have been developing NS001, an intranasal Naloxone powder nasal spray for the treatment of opioid overdose, or Intranasal Naloxone.

We currently have no FDA approved products. Our products have been tested on relatively small patient populations thus far.

Nasus Pharma Ltd.
CountryIsrael
Founded1
IndustryBiotechnology
SectorHealthcare
CEODan Teleman

Contact Details

Address:
Yigal Alon 65
Tel Aviv, 6744317
Israel
Phone+972.3.573.6632
Websitenasuspharma.com

Stock Details

Ticker SymbolNSRX
ExchangeNYSEAMERICAN
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0002029039
Employer ID51-6022712
SIC Code2834

Key Executives

NamePosition
Udi GilboaCo-Founder and Executive Chairman of the Board of Directors
Dr. Dalia MegiddoCo-Founder, Director, Chief Development Officer and Chief Medical Officer
Tair Lapidot, Pd.D.Vice President of Research and Development and Clinical Development
Galia Temtsin Kryaz, Ph.D.Director of CMC and Product Development
Oren ElmaliachDirector of Finance
Dr. Ronnie HershmanDirector

Latest SEC Filings

DateTypeTitle
Aug 7, 2025F-1/A[Amend] Registration statement for certain foreign private issuers
Jul 30, 2025FWPFree Writing Prospectus
Jul 28, 2025FWPFree Writing Prospectus
Jul 28, 2025F-1/A[Amend] Registration statement for certain foreign private issuers
Jul 9, 2025F-1Registration statement for certain foreign private issuers
May 21, 2025DRS/A[Amend] [Cover] Draft Registration Statement
May 12, 2025DRS/A[Amend] [Cover] Draft Registration Statement
Apr 29, 2025DRS/A[Amend] [Cover] Draft Registration Statement
Apr 16, 2025DRS/A[Amend] [Cover] Draft Registration Statement
Mar 21, 2025DRS/A[Amend] [Cover] Draft Registration Statement